Renal Arterial Disease and Hypertension

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Renal artery disease produces a spectrum of progressive clinical manifestations ranging from minor degrees of hypertension to circulatory congestion and kidney failure. Moderate reductions in renal blood flow do not induce tissue hypoxia or damage, making medical therapy for renovascular hypertension feasible. Several prospective trials indicate that optimized medical therapy using agents that block the renin-angiotensin system should be the initial management. Evidence of progressive disease and/or treatment failure should allow recognition of high-risk subsets that benefit from renal revascularization. Severe reductions in kidney blood flow ultimately activate inflammatory pathways that do not reverse with restoring blood flow alone.

Original languageEnglish (US)
Pages (from-to)65-79
Number of pages15
JournalMedical Clinics of North America
Volume101
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Hypertension
Kidney
Renovascular Hypertension
Renal Circulation
Renal Artery
Renin-Angiotensin System
Treatment Failure
Renal Insufficiency
Shock
Therapeutics
Hypoxia

Keywords

  • Angiotensin
  • Hypertension
  • Ischemic nephropathy
  • Kidney
  • Renal artery stenosis
  • Renovascular

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Renal Arterial Disease and Hypertension. / Textor, Stephen C.

In: Medical Clinics of North America, Vol. 101, No. 1, 01.01.2017, p. 65-79.

Research output: Contribution to journalReview article

@article{4f94a07bc0334d3aa4d9a9bc8aa4e529,
title = "Renal Arterial Disease and Hypertension",
abstract = "Renal artery disease produces a spectrum of progressive clinical manifestations ranging from minor degrees of hypertension to circulatory congestion and kidney failure. Moderate reductions in renal blood flow do not induce tissue hypoxia or damage, making medical therapy for renovascular hypertension feasible. Several prospective trials indicate that optimized medical therapy using agents that block the renin-angiotensin system should be the initial management. Evidence of progressive disease and/or treatment failure should allow recognition of high-risk subsets that benefit from renal revascularization. Severe reductions in kidney blood flow ultimately activate inflammatory pathways that do not reverse with restoring blood flow alone.",
keywords = "Angiotensin, Hypertension, Ischemic nephropathy, Kidney, Renal artery stenosis, Renovascular",
author = "Textor, {Stephen C}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.mcna.2016.08.010",
language = "English (US)",
volume = "101",
pages = "65--79",
journal = "Medical Clinics of North America",
issn = "0025-7125",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Renal Arterial Disease and Hypertension

AU - Textor, Stephen C

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Renal artery disease produces a spectrum of progressive clinical manifestations ranging from minor degrees of hypertension to circulatory congestion and kidney failure. Moderate reductions in renal blood flow do not induce tissue hypoxia or damage, making medical therapy for renovascular hypertension feasible. Several prospective trials indicate that optimized medical therapy using agents that block the renin-angiotensin system should be the initial management. Evidence of progressive disease and/or treatment failure should allow recognition of high-risk subsets that benefit from renal revascularization. Severe reductions in kidney blood flow ultimately activate inflammatory pathways that do not reverse with restoring blood flow alone.

AB - Renal artery disease produces a spectrum of progressive clinical manifestations ranging from minor degrees of hypertension to circulatory congestion and kidney failure. Moderate reductions in renal blood flow do not induce tissue hypoxia or damage, making medical therapy for renovascular hypertension feasible. Several prospective trials indicate that optimized medical therapy using agents that block the renin-angiotensin system should be the initial management. Evidence of progressive disease and/or treatment failure should allow recognition of high-risk subsets that benefit from renal revascularization. Severe reductions in kidney blood flow ultimately activate inflammatory pathways that do not reverse with restoring blood flow alone.

KW - Angiotensin

KW - Hypertension

KW - Ischemic nephropathy

KW - Kidney

KW - Renal artery stenosis

KW - Renovascular

UR - http://www.scopus.com/inward/record.url?scp=84996614653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996614653&partnerID=8YFLogxK

U2 - 10.1016/j.mcna.2016.08.010

DO - 10.1016/j.mcna.2016.08.010

M3 - Review article

C2 - 27884236

AN - SCOPUS:84996614653

VL - 101

SP - 65

EP - 79

JO - Medical Clinics of North America

JF - Medical Clinics of North America

SN - 0025-7125

IS - 1

ER -